STOCK TITAN

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Stoke Therapeutics, Inc. (STOK) to present at the 23rd Annual Needham Virtual Healthcare Conference. The presentation will focus on upregulating protein expression with RNA-based medicines. Live webcast available on the company's website. Replay accessible for 30 days.
Positive
  • None.
Negative
  • None.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.

A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

When will Stoke Therapeutics present at the 23rd Annual Needham Virtual Healthcare Conference?

Stoke Therapeutics will present at the conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.

What is the focus of Stoke Therapeutics' presentation at the conference?

The presentation will focus on upregulating protein expression with RNA-based medicines.

Where can investors watch the live webcast of Stoke Therapeutics' presentation?

Investors can watch the live webcast on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/.

How long will the replay of the webcast be available?

The replay of the webcast will be available for 30 days following the presentation.

Stoke Therapeutics, Inc.

NASDAQ:STOK

STOK Rankings

STOK Latest News

STOK Stock Data

751.05M
35.46M
4.64%
88.08%
10.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BEDFORD

About STOK

stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.